A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Trial details
- Registry ID
- NCT04576156
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as GRN163L
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor TreatmentNCT04576156 | Geron Corporation | Phase 3 | Active not recruiting | 2028-06-30Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |